Geron Announces FDA Oncologic Drugs Advisory Committee Votes in Favor of the Clinical Benefit/Risk Profile of Imetelstat for the Treatment of Transfusion-Dependent Anemia in Patients with Lower-Risk M

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. ABBV
2. MU
3. SPCX
4. ACN
5. IBM
6. TSLA
7. DPZ
8. NVDA
9. PRIM
10. META

Go back to Geron Announces FDA Oncologic Drugs Advisory Committee Votes in Favor of the Clinical Benefit/Risk Profile of Imetelstat for the Treatment of Transfusion-Dependent Anemia in Patients with Lower-Risk M

Geron Corporation (GERN) PT Raised to $5 at Goldman Sachs

March 15, 2024 3:51 AM EDT

Goldman Sachs analyst Corinne Jenkins raised the price target on Geron Corporation (NASDAQ: GERN) to $5.00 (from $4.00) while maintaining a Buy rating.

The analyst comments "

We expect GERN to trade higher tomorrow (+85-90% in after hours trading) following the FDA's Advisory... More